DelveInsight’s, “Type 1 Fibroblast Growth Factor Receptor Antagonists– Pipeline Insight, 2022,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Type 1 Fibroblast Growth Factor Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Type 1 Fibroblast Growth Factor Receptor Antagonists: Overview
Fibroblast growth factor receptors (FGFRs) play an important role in embryonic development, angiogenesis, wound healing, cell proliferation and differentiation. FGFR1 is a member of the Fibroblast Growth Factor family, comprising of 4 receptors and 18 Ligands. FGFR1 signalling downstream functions mainly via PI3K and MAPK pathways. Several ways of involvement of FGFR1 in cancer have been proposed: auto- and paracrine activation, amplification and overexpression.
Function – The FGFR1 protein spans the cell membrane, so that one end of the protein is inside the cell and the other end projects from the outer surface of the cell. This positioning allows the FGFR1 protein to interact with other proteins called fibroblast growth factors (FGFs) outside the cell and to receive signals that help the cell respond to its environment. When an FGF attaches to the FGFR1 protein, the receptor triggers a cascade of chemical reactions inside the cell that instruct the cell to undergo certain changes, such as maturing to take on specialized functions. This signaling is thought to play an important role in the development and growth of several parts of the body, including the brain, bones of the head and face (craniofacial bones), bones in the hands and feet, and the long bones in the arms and legs.
Type 1 Fibroblast Growth Factor Receptor Antagonists- Frequent tumor fibroblast growth factor receptor (FGFR) alterations are seen in many cancers, and include genetic amplifications, mutations, rearrangements and fusions. FGFR inhibitors target these receptor alterations and show promise as a drug class. FGF signaling inhibition dramatically reduces revascularization, hitting upon one of the hallmarks of cancers, angiogenesis, and reduces tumor burden in human tumors that depend on autocrine FGF signaling.
This segment of the Type 1 Fibroblast Growth Factor Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type 1 Fibroblast Growth Factor Receptor Antagonists Emerging Drugs
ABSK 091: Abbisko Therapeutics
ABSK 091 (formerly AZD 4547) is an orally bioavailable, small molecule, fibroblast growth factor receptor (FGFR) tyrosine kinase 1, 2 and 3 inhibitor, being developed and investigated by Abbisko therapeutics for the treatment of solid tumors. ABSK091 is an innovative small molecule FGFR inhibitor, of which Abbisko has the exclusive global rights for development, manufacture, and commercialization. In prior preclinical and multiple clinical studies, ABSK091 has demonstrated good safety and tolerability profiles, as well as preliminary efficacy in cancer patients harboring FGFR alterations.
Lucatinib: Clovis Oncology
Lucitanib (INN) is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours including metastatic breast cancer. It is a protein kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, as well as the fibroblast growth factor receptors 1 and 2, and the platelet-derived growth factor receptors alpha and beta.
Further product details are provided in the report……..
This segment of the report provides insights about the different Type 1 Fibroblast Growth Factor Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 12+ key companies which are developing the Type 1 Fibroblast Growth Factor Receptor Antagonists. The companies which have their Type 1 Fibroblast Growth Factor Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase II include, Abbisko Therapeutics.
DelveInsight’s report covers around 12+ products under different phases of clinical development like
Type 1 Fibroblast Growth Factor Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 1 Fibroblast Growth Factor Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 1 Fibroblast Growth Factor Receptor Antagonists drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Type 1 Fibroblast Growth Factor Receptor Antagonists: Overview
Pipeline Therapeutics
Therapeutic Assessment
Type 1 Fibroblast Growth Factor Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Type 1 Fibroblast Growth Factor Receptor Antagonists Collaboration Deals
Late Stage Products (Phase III)
Drug Name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ABSK 091: Abbisko Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
BFKB 8488A: Genentech
Drug profiles in the detailed report…..
Inactive Products
Type 1 Fibroblast Growth Factor Receptor Antagonists Key Companies
Type 1 Fibroblast Growth Factor Receptor Antagonists Key Products
Type 1 Fibroblast Growth Factor Receptor Antagonists- Unmet Needs
Type 1 Fibroblast Growth Factor Receptor Antagonists- Market Drivers and Barriers
Type 1 Fibroblast Growth Factor Receptor Antagonists- Future Perspectives and Conclusion
Type 1 Fibroblast Growth Factor Receptor Antagonists Analyst Views
Type 1 Fibroblast Growth Factor Receptor Antagonists Key Companies
Appendix
List of Table
Table 1: Total Products for Type 1 Fibroblast Growth Factor Receptor Antagonists
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Type 1 Fibroblast Growth Factor Receptor Antagonists
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Abbisko Therapeutics
• Eli Lilly and Company
• Debiopharm
• Eisai Co Ltd
• BridgeBio Pharma
• Hutchison MediPharma
• Clovis Oncology
• Servier
• Taiho Pharmaceutical
• Incyte Corporation
• Genentech
